Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.


Biomarker approach harnessed in trials of personalized medicine for bladder cancer

A multi-arm clinical trial reports results of testing a strategy for the treatment of bladder cancer that uses standard immunotherapy plus biomarker assessment and targeted therapies.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Fig. 1: Clinical-trial designs to test treatments for bladder cancer.


  1. 1.

    Powles, T. et al. Nat. Med. (2021).

  2. 2.

    Powles, T. et al. JAMA Oncol. 3, e172411 (2017).

    Article  Google Scholar 

  3. 3.

    Loriot, Y. et al. N. Engl. J. Med. 381, 338–348 (2019).

    CAS  Article  Google Scholar 

  4. 4.

    Robinson, B. D. et al. Nat. Commun. 10, 1–11 (2019).

    CAS  Article  Google Scholar 

  5. 5.

    Siefker-Radtke, A. O. et al. J. Clin. Oncol. 37, 4511–4511 (2019).

    Article  Google Scholar 

  6. 6.

    de Bono, J. et al. N. Engl. J. Med. 382, 2091–2102 (2020).

    Article  Google Scholar 

  7. 7.

    Jette, N. R. et al. Cancers (Basel) 12, 687 (2020).

    CAS  Article  Google Scholar 

  8. 8.

    Milowsky, M. I. et al. BJU Int. 112, 462–470 (2013).

    CAS  Article  Google Scholar 

  9. 9.

    Iyer, G. et al. Science 338, 221 (2012).

    CAS  Article  Google Scholar 

  10. 10.

    Wan, X., Harkavy, B., Shen, N., Grohar, P. & Helman, L. J. Oncogene 26, 1932–1940 (2007).

    CAS  Article  Google Scholar 

  11. 11.

    Powles, T. et al. Eur. Urol. 69, 450–456 (2016).

    CAS  Article  Google Scholar 

  12. 12.

    Sargent, D. J., Conley, B. A., Allegra, C. & Collette, L. J. Clin. Oncol. 23, 2020–2027 (2005).

    Article  Google Scholar 

Download references

Author information



Corresponding author

Correspondence to Sumanta K. Pal.

Ethics declarations

Competing interests

N. D. reports consulting for Vivreon Bioscience. S.K.P. reports consulting for Genentech, Aveo, Eisai, Roche, Pfizer, Novartis, Exelixis, Ipsen, BMS and Astellas.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Dizman, N., Meza, L. & Pal, S.K. Biomarker approach harnessed in trials of personalized medicine for bladder cancer. Nat Med 27, 761–763 (2021).

Download citation


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing